PathoVacs Inc.

Faster and universal vaccine development with PELS technology for fast antigen discovery.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Ames, IA, USA
  • Currency USD
  • Founded January 2009
  • Employees 3

Company Summary

An antigen is a part of a pathogen that triggers a immune response. Antigen discovery is the first and most difficult part of vaccine development. Finding a common antigen across multiple strains of a pathogen is even more difficult as it requires repeating antigen discovery over and over and over again. PathoVacs can compete in universal vaccine development because of its PELS technology which dramatically truncates antigen discovery.

Team

  • Manohar John
    CTO

    Founder and Chief Scientific Officer. Lead inventor of PELS technology while employed at Massachusetts General Hospital / Harvard Medical School. After that, John served as a Director, Molecular Genetics, and Head, Biomarker Discovery Program at Oragenics, Inc. based in Alachua, Florida.

  • Chuck Soponis
    CEO

    The business team will be formed around Mr. Chuck Soponis who has extensive experience leading nine startup companies in the fields of biotechnology, biopharmaceutical and medical diagnostics - achieving two IPOs and three acquisition exits.

  • Manohar John

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free